Can we help people safely stop opioid addiction meds? major study tests new strategies

NCT ID NCT04464980

Ongoing Disease control Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 22, 2026 · Updated 3 times

Summary

This study tests different medication and counseling combinations to improve how long people stay in treatment for opioid use disorder and whether they can safely stop medication without relapsing. Over 1,500 participants choose either buprenorphine or naltrexone and are randomly assigned to different doses or counseling approaches. The goal is to find the best ways to keep people in treatment and identify who can safely discontinue medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: buprenorphine and naltrexone (medications for opioid use disorder)
What this could lead to: If successful, this could identify the best strategies to help people stay in treatment longer and safely stop medication without relapsing.
What could go wrong: This is a Phase 2 study, so results are still early. The approaches tested may not work for everyone, and some participants may relapse during or after tapering off medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID USE DISORDER (OUD)

Contacts and locations

Locations

Adapt Integrated Health Care

Roseburg, Oregon, 97470, United States
Adapt Integrated Health Care

Winston, Oregon, 97496, United States
Aspire Health Partners

Orlando, Florida, 32806, United States
Bellevue Hospital Center

New York, New York, 10016, United States
Center for Psychiatric and Chemical Dependency Services (CPCDS)

Pittsburgh, Pennsylvania, 15213, United States
Chestnut Ridge Center

Morgantown, West Virginia, 26505, United States
Dartmouth Hitchcock - ATP

Lebanon, New Hampshire, 03766, United States
Gateway Community Services

Jacksonville, Florida, 32204, United States
Gibson Center for Behavioral Change

Cape Girardeau, Missouri, 63703, United States
Huntsman Mental Health Institute / University of Utah

Salt Lake City, Utah, 84108, United States
Internal Medicine Recovery Engagement Program (IM-REP)

Pittsburgh, Pennsylvania, 15219, United States
Liberation Programs, Inc.

Bridgeport, Connecticut, 06610, United States
McLean Hospital

Belmont, Massachusetts, 02478, United States
Mountain Manor / Maryland Treatment Centers

Baltimore, Maryland, 21229, United States
Operation PAR

Clearwater, Florida, 33760, United States
Shoreline Behavioral Health Services

Conway, South Carolina, 29526, United States
Square Medical Group, LLC

Newton, Massachusetts, 02458, United States
Stanley Street Treatment and Resources, Inc.

Fall River, Massachusetts, 02720, United States
Tarzana Treatment Centers, Inc.

Tarzana, California, 91356, United States
University of Arkansas for Medical Sciences (UAMS) / Center for Addiction Services and Treatment (CAST)

Little Rock, Arkansas, 72205, United States
University of New Mexico Addiction and Substance Abuse Program

Albuquerque, New Mexico, 87106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.